Physician profile
Heejin Kim
NPI 1306155395
$9,504.15
in general payments reported to CMS, 2019-2025
11 companies · $6,076 in 2025
The $6,076 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.01 · 2020: $54.65 · 2021: $159 · 2022: $69.59 · 2023: $438 · 2024: $2,696 · 2025: $6,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,960 · Food and Beverage: $1,891 · Travel and Lodging: $1,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,960.00 |
| Food and Beverage | $1,890.72 |
| Travel and Lodging | $1,358.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $8,954.25 | 2023-2025 | |
| Glaxosmithkline, LLC. | $194.39 | 2019-2025 | Trelegy Ellipta |
| Solta Medical, A Division of Bausch Health US, LLC | $167.74 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.50 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $31.08 | 2022 | |
| Jazz Pharmaceuticals INC. | $26.22 | 2021 | |
| Genzyme Corporation | $23.86 | 2021-2022 | |
| Octapharma USA, INC. | $16.83 | 2021 | |
| Alk-Abello, INC | $13.76 | 2020 | |
| Amgen INC. | $13.52 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heejin Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.